As patent due to expire, AHF calls on Gilead for 90% price cut on tenofovir-based drugs
Noting that with the patent ending and generics looming, USA-based global AIDS organization AIDS Healthcare Foundation (AHF) is calling on biotech giant Gilead Sciences (Nasdaq: GILD) to reduce the price of its tenofovir-based drug regimens - including Truvada (emtricitabine/tenofovir disoproxil fumarate) - by as much as 90%.
The California company has made billions off of sales of its tenofovir-based drugs since the Food and Drug Administration first approved Gilead’s tenofovir disoproxil fumarate (TDF), branded as Viread, on October 26, 2001, says the AHF, a vocal critic of runaway drug pricing. The patent is set to expire on December 15, 2017, with the patent on a pediatric version of the drug set to expire in early 2018.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze